跳转至内容
Merck
CN

P3643

Supelco

苯巴比妥标准液 溶液

1.0 mg/mL in methanol

别名:

5-乙基-5-苯基巴比妥酸 溶液

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C12H12N2O3
化学文摘社编号:
50-06-6
分子量:
232.24
MDL编号:
MFCD00066494
UNSPSC代码:
41116107
PubChem化学物质编号:
329820184

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

drug standard

drug control

Home Office Schedule 3; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet

浓度

1.0 mg/mL in methanol

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

pharmaceutical (small molecule)

包装形式

single component solution

储存温度

2-8°C

SMILES字符串

CCC1(C(=O)NC(=O)NC1=O)c2ccccc2

InChI

1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)

InChI key

DDBREPKUVSBGFI-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

51.8 °F - closed cup

闪点(°C)

11 °C - closed cup

个人防护装备

Eyeshields, Faceshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
062K8804

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Caroline A Crowther et al.
The Cochrane database of systematic reviews, (1)(1), CD000164-CD000164 (2010-01-22)
Preterm infants are at risk of periventricular haemorrhage. Phenobarbital might prevent ischaemic injury or reduce fluctuations in blood pressure and blood flow in the brain. To assess the benefits and harms of giving phenobarbital to women at risk of imminent
M Lundqvist et al.
Acta paediatrica (Oslo, Norway : 1992), 102(9), 863-867 (2013-06-07)
Treatment of neonatal seizures still relies primarily on phenobarbital, despite an estimated efficacy of less than 50% and concern over neurodegenerative side effects. The objective of this study was to evaluate the efficacy and safety of lidocaine as second-line treatment
Martin J Brodie et al.
Epilepsia, 53 Suppl 8, 40-46 (2012-12-12)
This article reviews the current position of phenobarbital using articles published since 2000 and speculates on its likely future contribution to epilepsy care. Over the last decade there have been no major double-blind randomized placebo-controlled or comparative trials with phenobarbital.
Dina Battino et al.
Epilepsia, 54(9), 1621-1627 (2013-07-16)
To analyze seizure control, dose adjustments, and other changes of antiepileptic drug (AED) treatment during pregnancy in a large cohort of women with epilepsy entering pregnancy on monotherapy with carbamazepine, lamotrigine, phenobarbital, or valproate. Seizure control and AED treatment were
Louis W C Chow et al.
Expert opinion on investigational drugs, 22(3), 299-307 (2013-02-12)
This prospective study aimed at investigating the efficacy and safety of the concurrent use of celecoxib (CXB) with 5-fluorouracil, epirubicin and cyclophosphamide (FEC), followed by docetaxel (T) in the neoadjuvant setting. A total of 64 invasive breast cancer patients were
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持